GIPP küsimustik täiendava kaitse tunnistuse teemal

Saatja: Liisa Laanemets <[email protected]> Saadetud: 22.01.2020 11:53 Adressaat: Liisa Laanemets <[email protected]> Teema: FW: GIPP küsimustik täiendava kaitse tunnistuse teemal Manused: image001.png; image002.png; image003.png; Questionnaire-transparency-SPC.docx Saatja: Henrik Trasberg Saatmisaeg: 22. jaanuar 2020. a. 10:27 Adressaat: Cady Kaisa Rivera <[email protected]>; Ülle Tamm Patendiamet <[email protected]> Koopia: Gea Lepik <[email protected]> Teema: GIPP küsimustik täiendava kaitse tunnistuse teemal Tere! Euroopa Komisjoni GIPP ekspertgrupist saadeti kõikide liikmesriikide patendiametitele vastamiseks meditsiinitoodete ja taimekaitsetoodete täiendava kaitse tunnistust puudutav küsimustik (lisatud manusena). Pöördun teie poole palvega käesolevale küsimustikule vastata. Küsimustiku eesmärk on saada parem ülevaade liikmesriikide praktikast seoses täiendava kaitse süsteemi läbipaistvusega. Oleksime tänulikud, kui saaksite küsimustikule vastata ja saata selle meile tagasi 5. veebruariks. Andke teada, kui on täiendavaid küsimusi/kommentaare. Parimate soovidega Henrik Trasberg Nõunik Intellektuaalse omandi ja konkurentsiõiguse talitus Õiguspoliitika osakond Justiitsministeerium +372 5200197 www.just.ee Questionnaire on SPC s addressed to EU patent offices NOTE: The following questions may need to be answered separately for medicinal products and for plant protection products , if there is a difference . Transparency issues Does the website of your national patent office provide for an online searchable database? If yes, with which search criteria (e.g. SPC number, applicant, product name , INN, etc . )? D o you make the documents of the file of a given SPC application accessible online (e.g. in PDF format)? If not, do you offer any other options for third parties to access the file of an SPC application (e.g. providing copies of the file)? Are these options provided free of charge or against payment of a fee? Do you b l a ck out confidential information on the publicly accessible documents of the file ? If so, which ? Do you r database provide links to any of the following reference documents : the basic patent ( e.g . on esp@cenet)? the marketing authorisation (e.g . on databases from medicine agencies)? Do you publish SPC-related information also in English? Do you identify the medicinal product with the INN, if available, or otherwise ? (please specify) Do you regularly provid e the EPO with detailed information on SPCs (filing of an SPC application, granting of an SPC, revocation/lapse of an SPC, payments of renewal fees, etc.) ? Which of the following sources would you consider to be the most suitable for providing centralised access to SPC information? EPO databases as existing today (e.g. esp@cenet, European patent register) EPO databases with improvements (please specify which ones) A new centralized website providing comprehensive information on SPCs (e.g. including all relevant dates and reference numbers, as well as links to the relevant patents and marketing authorisations, SPC manufacturing waiver notifications, etc.) How long does it take , on average, from the date of filing of an SPC application, its grant or revocation, etc . until the publication of th e se events? Do you publish SPC information beyond the legal requirements under Articles 9, 11 and 17 of Regulation 469/2009 and corresponding p rovisions of Regulation 1610/96 ? If so, wh ich? Other issues Do you accept electronic filings of SPC applications ? Is it possible to download certified copies of a granted SPC from your website ? Is the appointment of a national representative required for the filing and prosecution of an SPC application before your NPO? Do you provide any fee incentives for particular SPC applicant categories (e.g. SMEs or public research bodies)? If yes, which ones ? Do you have proposals to further improve the SPC system – e.g. reduce administrative burden, costs, improve transparency and/or user-friendliness ?